Gamma scintigraphy for testing bioequivalence: A case study on two cromolyn sodium nasal spray preparations

被引:20
作者
Al-Ghananeem, Abeer M. [1 ]
Sandefer, Erik P. [2 ]
Doll, Walter J. [2 ]
Page, Richard C. [2 ]
Chang, Yunik [3 ]
Digenis, George A. [1 ]
机构
[1] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA
[2] Scintipharma Inc, Lexington, KY 40503 USA
[3] Dow Pharmaceut Sci, Petaluma, CA 94954 USA
关键词
nasal; deposition; clearance; cromolyn sodium; gamma scintigraphy; bioequivalence;
D O I
10.1016/j.ijpharm.2008.01.040
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The present work was carried out to study the deposition patterns and clearance of technetium-99m (Tc-99m) DTPA labeled cromolyn sodium (CS) solutions when administered from two different CS nasal products using gamma scintigraphy. Five healthy volunteers received a single dose with complete crossover design involving treatment A (test formulation) and treatment B (reference formulation). The deposition patterns as well as the changes in distribution of the radiolabeled CS solutions due to the mucociliary transport were monitored by gamma scintigraphy. Primary deposition of the aforementioned nasal solutions occurred in the anterior portion of the nose. After migration into the posterior nasal cavity, the solutions were rapidly cleared by ciliary action into the nasopharynx where it was swallowed. The test product of cromolyn sodium was shown to be equivalent to the reference product with regard to nasal deposition and clearance. The results from this study indicate that external gamma scintigraphy can be used to demonstrate the equivalence of nasal sprays that are intended for local therapeutic action where the drug is not systemically absorbed into the blood circulation. Furthermore, a non-invasive imaging method such as rhinoscintigraphy may prove to be a useful technique to be utilized during the regulatory approval process for local-acting nasal products, and may facilitate the early introduction of these products to the market. (C) 2008 Published by Elsevier B.V.
引用
收藏
页码:70 / 76
页数:7
相关论文
共 35 条
[1]
Al-Ghananeem Abeer M, 2002, AAPS PharmSciTech, V3, pE5
[2]
DISTRIBUTION AND REMOVAL OF HUMAN-SERUM ALBUMIN TC-99M 99M INSTILLED INTRANASALLY [J].
AOKI, FY ;
CRAWLEY, JCW .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1976, 3 (05) :869-878
[3]
THE DEPOSITION AND CLEARANCE OF LIPOSOME-ENTRAPPED TC-99M-DTPA IN THE HUMAN RESPIRATORY-TRACT [J].
BARKER, SA ;
TAYLOR, KMG ;
SHORT, MD .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 102 (1-3) :159-165
[4]
CHANG Y, 1996, PHARM RES, V13, P175
[5]
Development of a novel nasal nicotine formulation comprising an optimal pulsatile and sustained plasma nicotine profile for smoking cessation [J].
Cheng, YH ;
Watts, P ;
Hinchcliffe, M ;
Hotchkiss, R ;
Nankervis, R ;
Faraj, NF ;
Smith, A ;
Davis, SS ;
Illum, L .
JOURNAL OF CONTROLLED RELEASE, 2002, 79 (1-3) :243-254
[6]
Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica [J].
Cheng, YS ;
Fu, CS ;
Yazzie, D ;
Zhou, Y .
JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 2001, 14 (02) :255-266
[7]
Nasal administration of a physostigmine analogue (NXX-066) for Alzheimer's disease to rats [J].
Dahlin, M ;
Björk, E .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 212 (02) :267-274
[8]
Delivery of nasal powders of beta-cyclodextrin by insufflation [J].
DeAscentiis, A ;
Bettini, R ;
Caponetti, G ;
Catellani, PL ;
Peracchia, MT ;
Santi, P ;
Colombo, P .
PHARMACEUTICAL RESEARCH, 1996, 13 (05) :734-738
[9]
DIGENIS GA, 1991, CRIT REV THER DRUG, V7, P309
[10]
Gamma scintigraphy: an evolving technology in pharmaceutical formulation development - Part 2 [J].
Digenis, GA ;
Sandefer, EP ;
Page, RC ;
Doll, WJ .
PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1998, 1 (04) :160-165